FY2026 Earnings Forecast for XENE Issued By Bloom Burton

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at Bloom Burton issued their FY2026 EPS estimates for Xenon Pharmaceuticals in a report released on Tuesday, October 7th. Bloom Burton analyst D. Martin expects that the biopharmaceutical company will post earnings of ($4.89) per share for the year. Bloom Burton has a “Strong-Buy” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Bloom Burton also issued estimates for Xenon Pharmaceuticals’ FY2027 earnings at ($4.65) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.04). During the same quarter last year, the company posted ($0.75) EPS.

A number of other research analysts have also recently commented on the stock. Wedbush upped their price target on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Tuesday, August 12th. Wells Fargo & Company assumed coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, September 3rd. They issued an “overweight” rating and a $48.00 price target on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, September 2nd. Chardan Capital restated a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday. Finally, William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.30.

Xenon Pharmaceuticals Stock Up 0.2%

XENE stock opened at $39.25 on Wednesday. The firm’s fifty day simple moving average is $37.23 and its two-hundred day simple moving average is $34.15. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of -11.06 and a beta of 1.14. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.00.

Institutional Trading of Xenon Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC purchased a new stake in Xenon Pharmaceuticals in the second quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Xenon Pharmaceuticals in the first quarter worth about $30,000. Elevation Point Wealth Partners LLC purchased a new stake in Xenon Pharmaceuticals in the second quarter worth about $32,000. Osaic Holdings Inc. lifted its stake in Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the period. Finally, L1 Capital Pty Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at about $41,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Ian Mortimer sold 25,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total value of $1,004,000.00. Following the completion of the sale, the chief executive officer directly owned 31,302 shares of the company’s stock, valued at $1,257,088.32. This represents a 44.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.07% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.